AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a significant Phase 2b clinical study titled A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) With Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele. The study aims to assess the efficacy, safety, and tolerability of the drug AZD2693 in adult participants with NASH and fibrosis who carry the PNPLA3 148M risk allele, a genetic variant associated with liver disease.
The intervention being tested is AZD2693, administered as a subcutaneous injection once per month. This drug is designed to treat non-cirrhotic NASH with fibrosis, a condition that currently lacks effective treatment options.
The study employs a randomized, double-blind, placebo-controlled design with a parallel intervention model. It involves quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment.
The study began on March 15, 2023, with an estimated completion date set for August 5, 2025. These dates are crucial as they guide investors on the timeline for potential data releases and regulatory milestones.
This clinical update could positively influence AstraZeneca’s stock performance by showcasing its commitment to addressing unmet medical needs in the NASH market. As competitors also race to develop treatments for NASH, AstraZeneca’s progress could enhance investor sentiment and position it favorably within the industry.
The study is ongoing, and further details are available on the ClinicalTrials portal.